RXSIGHT INC

RXSTNASDAQ

🏆 #2983 by market capEarnings Nov 4US Equity

$7.04▲ $0.50 (+7.15%)

🌅 Pre-market$6.89▼ 2.13%Regular close · extended-hours price shown

1h—

24h▲ 7.2%

7d▲ 11.7%

14d▲ 14.7%

30d▲ 38.9%

1y▼ 4.1%

🏦Market Cap

$291M

Small Cap

📈Revenue Growth (YoY)

-13.2%

Declining

📊Gross Margin

77.5%

High

💵FCF Margin

—

⚖️P/S Ratio

2.1x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $6.95 – $7.09
52-Week Range: $4.48 – $13.22
Volume: $3.11B
Avg Volume: $3.28B
Shares Outstanding: 41.4M
Next Earnings: Oct 4, 2026

Fundamentals Snapshot

Annual Revenue: $134M
Last Q Revenue: $34M
P/E Ratio: —
P/S Ratio: 2.1x
EPS (TTM): $-1.14
Dividend Yield: —

Why Investors Own RXST

✓High-growth profile — revenue up +6.8% YoY with expanding US Equity exposure.
✓Healthy economics — 32% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$134M▲ +1.5% YoY

Gross Margin (TTM)

32.4%▲ +4.1% YoY

Operating Income (TTM)

$31M▲ +1.5% YoY

Free Cash Flow (TTM)

$8M▲ +1.5% YoY

About RXSIGHT INC

As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.

🦦